Value Added Services in Cardiometabolic Diseases -- Payer views
Pharma's Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder there is a widespread cynical view among payers that many 'beyond the pill' support services are little more than a marketing ploy. How can Pharma get back on track and deliver sustained VAS that innovatively support long-term cardiometabolic disease patients, change behaviour and build trust with payers? Value-added Services in Cardiometabolic Diseases meets head-on the current criticism of many VAS initiatives, and through the hard-hitting insights of senior US and EU payers, clearly identifies the key VAS design, development and areas for improvement that industry needs to address.
Answering key questions:
Reasons to buy this report
VAS have become a standard feature of pharma's outreach and companies can point to a raft of monitoring, education and health support services that have made a real impact. So why are payers sceptical and how is that impacting pharma's prospects? Short lived VAS are not building trust with payers or fully meeting the long-term needs of patients – especially in chronic conditions such as diabetes. It can be better. In this report experienced US and EU payers identify what good, on-target VAS look like, how working with payers can lead to better VAS solutions and how sharing outcomes data can help prove product value to a company's commercial benefit.
This report will enable you to:
Executive summary
Research methodology and objectives
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Answering key questions:
Reasons to buy this report
VAS have become a standard feature of pharma's outreach and companies can point to a raft of monitoring, education and health support services that have made a real impact. So why are payers sceptical and how is that impacting pharma's prospects? Short lived VAS are not building trust with payers or fully meeting the long-term needs of patients – especially in chronic conditions such as diabetes. It can be better. In this report experienced US and EU payers identify what good, on-target VAS look like, how working with payers can lead to better VAS solutions and how sharing outcomes data can help prove product value to a company's commercial benefit.
This report will enable you to:
- Plan VAS into the product lifecycle to support patients with chronic cardiometabolic diseases
- Leverage real world VAS outcomes data to support value claims with payers
- Work collaboratively with payers to design innovative VAS programmes
- Learn why working with trusted independent 3rd parties to deliver VAS will gain payer approval
- Innovate to address non-adherence in a patient-centric way
- Understand how US and EU5 payers' views of VAS vary and nuance your programmes to meet local conditions
Executive summary
Research methodology and objectives
- Experts interviewed for this report
- What are cardiometabolic diseases?
- What are value-added services?
- Key insights on the role of value-added services in cardiometabolic diseases
- The challenge of behavioural change
- Do VAS influence pricing & reimbursement decisions?
- Types of value-added services
- Table: How payers rate different types of VAS
- Fitness trackers
- Education and disease management
- Services that support adherence and compliance
- VAS that connect patients with HCPs
- Reminders to take medication
- Figure: Medication reminder Apps
- Branded versus unbranded VAS
- Pharma versus third party providers
- Pharma collaboration with technology companies for cardiometabolic VAS
- Case study: Roche acquisition of mySugr
- Case study: Novo Nordisk's Cornerstones4Care, powered by Glooko
- Key insights on opportunities for new VAS
- What payers want from VAS
- Evidence of improved patient outcomes
- Figure: Increasing the value-proposition of VAS
- Real-world data that doctors can access
- Cost savings
- Changing behaviour is a key objective
- Collaboration with payers to develop VAS
- Harnessing new technology for VAS
- The top opportunities for pharma
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY AND OBJECTIVES
2.1 Experts interviewed for this report
3. DEFINITIONS AND OVERVIEW
3.1 What are cardiometabolic diseases?
3.2 What are value-added services?
4. THE ROLE OF VALUE-ADDED SERVICES IN CARDIOMETABOLIC DISEASES
4.1 The challenge of behavioural change
4.2 Do VAS influence pricing & reimbursement decisions?
4.3 Types of value-added services
4.3.1 Fitness trackers
4.3.2 Education and disease management
4.3.3 Services that support adherence and compliance
4.3.4 VAS that connect patients with HCPs
4.3.5 Reminders to take medication
4.4 Branded versus unbranded VAS
4.5 Pharma versus third party providers
4.6 Collaboration with technology companies for cardiometabolic VAS
5. OPPORTUNITIES FOR NEW VAS IN CARDIOMETABOLIC DISEASE
5.1 What payers want from VAS
5.1.1 Evidence of improved patient outcomes
5.1.2 Real-world data that doctors can access
5.1.3 Cost savings
5.2 Changing behaviour is a key objective
5.3 Collaboration with payers to develop VAS
5.4 Harnessing new technology for VAS
5.5 The top opportunities for pharma
6. KEY TAKEAWAYS
2. RESEARCH METHODOLOGY AND OBJECTIVES
2.1 Experts interviewed for this report
3. DEFINITIONS AND OVERVIEW
3.1 What are cardiometabolic diseases?
3.2 What are value-added services?
4. THE ROLE OF VALUE-ADDED SERVICES IN CARDIOMETABOLIC DISEASES
4.1 The challenge of behavioural change
4.2 Do VAS influence pricing & reimbursement decisions?
4.3 Types of value-added services
4.3.1 Fitness trackers
4.3.2 Education and disease management
4.3.3 Services that support adherence and compliance
4.3.4 VAS that connect patients with HCPs
4.3.5 Reminders to take medication
4.4 Branded versus unbranded VAS
4.5 Pharma versus third party providers
4.6 Collaboration with technology companies for cardiometabolic VAS
5. OPPORTUNITIES FOR NEW VAS IN CARDIOMETABOLIC DISEASE
5.1 What payers want from VAS
5.1.1 Evidence of improved patient outcomes
5.1.2 Real-world data that doctors can access
5.1.3 Cost savings
5.2 Changing behaviour is a key objective
5.3 Collaboration with payers to develop VAS
5.4 Harnessing new technology for VAS
5.5 The top opportunities for pharma
6. KEY TAKEAWAYS
